MedTrace Logo

National Pregnancy Registry for Psychiatric Medications

NCT01246765 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-10-24

No results posted yet for this study

Summary

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

Conditions

  • Pregnant Women
  • Psychotropic Drugs

Sponsors & Collaborators

  • Alkermes, Inc.

    collaborator INDUSTRY

  • Eisai Inc.

    collaborator INDUSTRY

  • Otsuka America Pharmaceutical

    collaborator INDUSTRY

  • Supernus Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Sage Therapeutics

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Lee S Cohen, MD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2033-12-31
Completion
2033-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246765 on ClinicalTrials.gov